Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Increase in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 74,418 shares, a growth of 286.3% from the November 30th total of 19,264 shares. Based on an average trading volume of 172,559 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the company’s stock are sold short. Approximately 0.1% of the company’s stock are sold short. Based on an average trading volume of 172,559 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On Xtant Medical

Several institutional investors have recently modified their holdings of XTNT. Vanguard Group Inc. lifted its holdings in Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares during the period. Mink Brook Asset Management LLC increased its position in shares of Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Xtant Medical during the 2nd quarter valued at $4,875,000. Nantahala Capital Management LLC raised its stake in shares of Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after purchasing an additional 57,000,000 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Xtant Medical in the 2nd quarter worth about $26,000. 69.33% of the stock is owned by institutional investors.

Xtant Medical Stock Down 0.3%

XTNT stock traded down $0.00 during mid-day trading on Thursday, reaching $0.78. 71,926 shares of the company traded hands, compared to its average volume of 240,869. The firm’s 50 day moving average price is $0.73 and its 200 day moving average price is $0.67. Xtant Medical has a fifty-two week low of $0.34 and a fifty-two week high of $0.95. The stock has a market cap of $108.92 million, a price-to-earnings ratio of 77.88 and a beta of -0.05. The company has a quick ratio of 1.06, a current ratio of 2.21 and a debt-to-equity ratio of 0.35.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its quarterly earnings data on Monday, November 10th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $32.70 million. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%.

Wall Street Analysts Forecast Growth

Separately, BTIG Research dropped their price objective on shares of Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Xtant Medical currently has a consensus rating of “Buy” and a consensus target price of $1.50.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.